BIOTECH 2011 NJ/PA/DE Case Studies
•Download as PPT, PDF•
1 like•221 views
Three companies faced challenges commercializing new products in the US healthcare system: Company A scrapped a lab diagnostic project due to lack of differentiated clinical value and reimbursement approval. Company B's injectable biologic faced poor adoption due to label restricting administration and causing coverage under medical instead of pharmacy benefit with more hurdles. Company C helped increase utilization of its artificial disc replacement through an appeals program that collected patient quality of life data to submit personalized appeal packages on behalf of surgeons and patients, lowering administrative burden.
![Company with no US commercialization experience created strategic partnerships to manufacturer, distribute and market a lab-based diagnostic. Case Study: EU Diagnostic Company (Co. A) ,[object Object],[object Object],[object Object],Co. A invested in a product that had no commercial value in the US due to reimbursement and payment issues and scrapped the project. “ Look Before You Leap” - Consider the commercial reimbursement landscape before investing! Results & Lessons Learned](https://image.slidesharecdn.com/biotech2011powerfulpayernathanwhiteinventivhealthcasestudies-111031134752-phpapp02/85/BIOTECH-2011-NJ-PA-DE-Case-Studies-1-320.jpg)
![Company with some US commercialization experience launched a lyo-formulated SQ injectable biologic for a chronic disease into a very crowded market. Case Study: Mid-size Biotech (Co. B) ,[object Object],[object Object],[object Object],Co. B could have considered a pro-active risk management program to mitigate concern with patient education and altered the label pre-approval. “ Consider The Label” – nuances in the label can have drastic repercussions on the future reimbursement scenario! Results & Lessons Learned](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)